Irbesartán/Hidroclorotiazida Normon

Irbesartan, the active ingredient in Irbesartán/Hidroclorotiazida Normon, is an Angiotensin II receptor blocker presented as a fixed‑dose combination tablet for oral use. It is used to treat hypertension, often in patients who require both blood‑pressure reduction and diuresis.

GNH USA supplies Irbesartán/Hidroclorotiazida Normon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and renal sodium handling to lower elevated blood pressure.

Essential hypertension: reduces systolic and diastolic blood pressure to target levels. Stage 1 hypertension: helps achieve recommended blood‑pressure goals when monotherapy is insufficient. Stage 2 hypertension: used as part of combination therapy for patients needing stronger pressure control.

The following adverse reactions have been reported with the fixed‑dose combination of irbesartan and hydrochlorothiazide.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache, often mild to moderate in intensity. - Fatigue or general weakness. - Increased urinary frequency or volume. - Electrolyte disturbances such as low potassium or sodium. - Mild gastrointestinal discomfort, including nausea.

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance requiring medical attention. - Hyperkalemia, particularly in patients with renal impairment. - Angioedema or swelling of the face, lips, or throat. - Acute kidney injury or significant rise in serum creatinine. - Severe hypotension leading to syncope. - Allergic reactions such as rash, pruritus, or urticaria.

Before initiating therapy, clinicians should consider several safety measures.

Monitor blood pressure regularly: adjust dose based on response. Assess renal function: check serum creatinine and eGFR before and during treatment. Check electrolytes: especially potassium and sodium levels. Use caution in hepatic impairment: dose adjustments may be needed. Avoid in patients with known hypersensitivity to either component. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/hydrochlorothiazide may interact with several medicines; awareness of interaction severity guides management.

Major Interactions (Avoid): - Aliskiren in patients with diabetes or renal impairment. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Lithium: increased lithium levels and toxicity. - ACE inhibitors or other ARBs: additive renal effects. - NSAIDs: may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives: may cause excessive blood‑pressure lowering. - CYP3A4 inhibitors (e.g., ketoconazole): may increase irbesartan levels. - Antidiabetic agents: diuretic‑induced changes in glucose control. - Anticoagulants: potential for altered INR with thiazide‑induced volume changes.